Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.59 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322836 | 0.87 | CARM1 (0.59) | CARM1PRMT6TAAR1 | |
| SCHEMBL6957735 | 0.83 | MC4R (0.65) | CARM1PRMT6 | |
| SCHEMBL8117468 | 0.82 | MAPT (0.67) | MAPK1MAPTKDM4E | |
| SCHEMBL1507008 | 0.80 | LMNA (0.67) | PRMT6MAPTKDM4ENCF1 | |
| SCHEMBL10686392 | 0.80 | SIGMAR1 (0.60) | MAPTKDM4E | |
| SCHEMBL8328840 | 0.80 | CARM1 (0.42) | CARM1PRMT6MAPK1MAPT | |
| SCHEMBL24322486 | 0.80 | KCNJ1 (0.57) | MAPK1NCF1 | |
| SCHEMBL9096825 | 0.79 | MAPT (0.56) | MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL10502749 | 0.79 | SIGMAR1 (0.59) | MAPTKDM4E | |
| SCHEMBL23751084 | 0.78 | MAPK1 (0.55) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | CARM1 4394/4885PRMT6 2880/4885MAPK1 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.